Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies

Programmed cell death ligand-1 (PD-L1) expression levels in patient tumor samples have proven clinical utility across various cancer types. Several independently developed PD-L1 immunohistochemical (IHC) predictive assays are commercially available. Published studies using the VENTANA PD-L1 (SP263)...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mod Pathol
Egile Nagusiak: Lawson, Nicola L., Dix, Carly I., Scorer, Paul W., Stubbs, Christopher J., Wong, Edmond, Hutchinson, Liam, McCall, Eileen J., Schimpl, Marianne, DeVries, Emma, Walker, Jill, Williams, Gareth H., Hunt, James, Barker, Craig
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group US 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8075905/
https://ncbi.nlm.nih.gov/pubmed/31558782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41379-019-0372-z
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak